See What HealthDay Can Do For You
Contact Us

β-Blockers Linked to Reduced Mortality in HFrEF, A-Fib

Reduction in all-cause mortality, but not hospitalization, regardless of pattern, burden of a-fib

stethoscope

THURSDAY, Jan. 12, 2017 (HealthDay News) -- β-blockers are associated with significantly reduced mortality, but not hospitalizations, in patients with heart failure and reduced ejection fraction (HFrEF) and atrial fibrillation (AF), according to a study published online Jan. 11 in JACC: Heart Failure.

Julia Cadrin-Tourigny, M.D., from the Université de Montréal, and colleagues examined the impact of β-blockers on mortality and hospitalizations in patients with AF and HFrEF in the AF-CHF trial. Among 1,376 subjects randomized in the trial, the authors propensity-matched those without β-blockers at baseline to a maximum of two exposed patients.

The researchers found that β-blockers correlated with significantly lower all-cause mortality (hazard ratio [HR], 0.721; 95 percent confidence interval [CI], 0.549 to 0.945; P = 0.0180) but not hospitalizations (HR, 0.886; 95 percent CI, 0.715 to 1.100; P = 0.2232) during a median follow-up of 37 months. In sensitivity analyses that modeled β-blockers as a time-dependent variable the results were similar (HR for all-cause mortality, 0.668; 95 percent CI, 0.511 to 0.874; P = 0.0032; HR for hospitalizations, 0.814; 95 percent CI, 0.653 to 1.014; P = 0.0658). With respect to mortality and hospitalizations, there were no significant interactions for β-blockers and pattern or burden of AF.

"These results support current evidence-based recommendations for β-blockers in patients with HFrEF, whether or not they have associated AF," the authors write.

Full Text

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.